To assess patient-reported outcomes with Nirmatrelvir/ritonavir (NMV/r) in nonhospitalized adults with COVID-19 at high risk of severe disease.
Key Findings:
NMV/r treatment resulted in a significant 3-day reduction in median time to return to usual health (HR 1.3, P < .0001).
Patients experienced a 1-day reduction in median time to return to usual activities (HR 1.2, P < .0001).
Significantly shorter times to sustained resolution and alleviation of overall symptoms were reported (HR 1.2, P < .0002 and P < .0001, respectively).
No significant differences were observed in WPAI-COVID-19 or EQ-5D-5L results between treatment groups.
Interpretation:
Patients receiving NMV/r reported a quicker return to health and reduced symptom severity compared to placebo, indicating the treatment's effectiveness in improving patient-reported outcomes.
Limitations:
PROs were collected as secondary endpoints and may not fully represent the overall treatment impact.
Responses were only available from a subset of participants who enrolled after an initial cohort.
Conclusion:
Nirmatrelvir/ritonavir treatment significantly improved patient-reported outcomes in high-risk adults with COVID-19, highlighting its potential benefits in managing the disease.
